StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma operating margin

Operating margin is operating income as a percentage of revenue.

Xeris Biopharma's operating margin for the twelve months ending Jun 30, 2026 was 10.9%. For fiscal 2025 it was 8.5%, against -16.6% the year before. The highest annual figure on record is 8.5% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20258.5%+25.1
FY2024Dec 31, 2024-16.6%+10.3
FY2023Dec 31, 2023-26.8%+47.5
FY2022Dec 31, 2022-74.3%+157.9
FY2021Dec 31, 2021-232.2%+176.6
FY2020Dec 31, 2020-408.8%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 20265.6%−0.6
Q1 FY2026Mar 31, 20269.5%+14.7
Q4 FY2025Dec 31, 202519.5%+16.8
Q3 FY2025Sep 30, 20259.0%+32.8
Q2 FY2025Jun 30, 20256.3%+23.3
Q1 FY2025Mar 31, 2025-5.1%+29.9
Q4 FY2024Dec 31, 20242.8%+25.0
Q3 FY2024Sep 30, 2024-23.8%−13.6
Q2 FY2024Jun 30, 2024-17.0%+25.0
Q1 FY2024Mar 31, 2024-35.1%+4.9
Q4 FY2023Dec 31, 2023-22.2%+23.6
Q3 FY2023Sep 30, 2023-10.2%+53.0
Q2 FY2023Jun 30, 2023-42.0%+32.7
Q1 FY2023Mar 31, 2023-40.0%+91.7
Q4 FY2022Dec 31, 2022-45.8%+179.5
Q3 FY2022Sep 30, 2022-63.2%+157.1
Q2 FY2022Jun 30, 2022-74.7%+214.8
Q1 FY2022Mar 31, 2022-131.7%+72.6
Q4 FY2021Dec 31, 2021-225.3%+37.2
Q3 FY2021Sep 30, 2021-220.2%−74.1
Q2 FY2021Jun 30, 2021-289.5%–
Q1 FY2021Mar 31, 2021-204.3%–
Q4 FY2020Dec 31, 2020-262.5%–
Q3 FY2020Sep 30, 2020-146.2%–

More Xeris Biopharma figures

See a number that looks wrong?